Compare · BLI vs DFTX
BLI vs DFTX
Side-by-side comparison of Berkeley Lights Inc. (BLI) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLI and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.60B, about 7.8x BLI ($591.8M).
- DFTX has hit the wire 8 times in the past 4 weeks while BLI has been quiet.
- BLI has more recent analyst coverage (13 ratings vs 8 for DFTX).
- Company
- Berkeley Lights Inc.
- Definium Therapeutics Inc.
- Price
- $1.19-6.67%
- $32.12-6.23%
- Market cap
- $591.8M
- $4.60B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 8
- Recent ratings
- 13
- 8
BLI
Berkeley Lights Inc.
Berkeley Lights, Inc., a digital cell biology company, focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The company offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software. It serves in North America, the Asia Pacific, and Europe. The company was incorporated in 2011 and is headquartered in Emeryville, California.
Latest BLI
- Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
- SEC Form SC 13G/A filed by Berkeley Lights Inc. (Amendment)
- SEC Form 15-12G filed by Berkeley Lights Inc.
- Kadia Siddhartha returned 1,240,689 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chiminski John R returned 112,465 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Silvester Peter returned 64,596 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Hopfield Jessica returned 105,207 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Joshi Mehul returned 65,013 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Hobbs Eric returned 244,816 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Moritz Michael J returned 1,451,925 shares to the company (SEC Form 4)
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Analyst initiated coverage on Definium Therapeutics with a new price target
- Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 144 filed by Definium Therapeutics Inc.
- SEC Form 144 filed by Definium Therapeutics Inc.